ArticleFrontiers in oncology2023

Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma.

Manato Ohsawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.